Ajai Chari Selected Research

Immunomodulating Agents

11/2021	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
9/2021	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
2/2021	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.
1/2020	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
1/2020	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
1/2020	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
11/2016	Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
4/2016	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ajai Chari Research Topics

Disease

120	Multiple Myeloma 04/2024 - 09/2010
20	Neoplasms (Cancer) 04/2024 - 01/2013
6	Infections 01/2024 - 01/2017
4	Agammaglobulinemia (Hypogammaglobulinemia) 11/2023 - 01/2020
4	Disease Progression 11/2021 - 05/2015
3	Fatigue 12/2021 - 04/2016
3	COVID-19 01/2021 - 06/2020
3	Smoldering Multiple Myeloma 01/2021 - 01/2018
3	Hypertension (High Blood Pressure) 11/2020 - 10/2018
3	Neutropenia 01/2020 - 01/2017
3	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 07/2010
2	Chromosome Aberrations (Chromosome Abnormalities) 04/2024 - 01/2013
2	Body Weight (Weight, Body) 12/2022 - 11/2022
2	Thrombocytopenia (Thrombopenia) 12/2021 - 01/2020
2	Nausea 12/2021 - 01/2020
2	Lymphoma (Lymphomas) 01/2016 - 12/2009
2	Plasma Cell Neoplasms 10/2013 - 10/2012
1	Thrombosis (Thrombus) 11/2022
1	Cytokine Release Syndrome 09/2021
1	Cytopenia 09/2021
1	Bone Diseases (Bone Disease) 12/2020
1	Melanoma (Melanoma, Malignant) 02/2020
1	Hyponatremia 01/2020
1	Weight Loss (Weight Reduction) 01/2020
1	Diarrhea 01/2020
1	Vomiting 01/2020

Drug/Important Bio-Agent (IBA)

32	Dexamethasone (Maxidex)FDA LinkGeneric 04/2024 - 11/2016
31	daratumumabIBA 04/2024 - 01/2016
19	Lenalidomide (CC 5013)FDA Link 04/2024 - 01/2016
18	Bortezomib (Velcade)FDA Link 04/2024 - 09/2010
17	Proteasome InhibitorsIBA 11/2023 - 09/2010
16	selinexorIBA 05/2023 - 01/2018
14	Monoclonal AntibodiesIBA 11/2023 - 04/2016
14	carfilzomibIBA 05/2023 - 12/2014
8	Immunomodulating AgentsIBA 11/2021 - 04/2016
7	B-Cell Maturation AntigenIBA 03/2024 - 01/2020
7	Proteins (Proteins, Gene)FDA Link 01/2024 - 11/2016
6	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 03/2024 - 01/2020
6	Bispecific AntibodiesIBA 01/2024 - 09/2021
5	Immunoglobulins (Immunoglobulin)IBA 11/2023 - 10/2012
5	ixazomibIBA 12/2022 - 09/2016
4	Chimeric Antigen ReceptorsIBA 03/2024 - 01/2023
3	belantamab mafodotinIBA 12/2023 - 01/2020
3	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 01/2020
3	PanobinostatIBA 11/2021 - 09/2018
3	Exportin 1 ProteinIBA 01/2021 - 01/2018
3	Melphalan (Alkeran)FDA LinkGeneric 11/2020 - 03/2016
3	AntigensIBA 02/2020 - 01/2017
2	Intravenous Immunoglobulins (IVIG)FDA Link 11/2023 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 01/2019
2	filanesibIBA 01/2022 - 11/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2020
2	KinesinsIBA 01/2022 - 11/2016
2	Immunoglobulin G (IgG)IBA 11/2020 - 06/2020
2	ibrutinibIBA 08/2020 - 11/2018
2	fibrin fragment D (D-dimer)IBA 06/2020 - 01/2020
2	Ferritins (Ferritin)IBA 06/2020 - 01/2020
2	pomalidomideIBA 01/2020 - 01/2017
2	ParaproteinsIBA 10/2013 - 12/2009
1	Adenosine Monophosphate (AMP)IBA 04/2024
1	elotuzumabIBA 04/2024
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2024
1	Surface Antigens (Surface Antigen)IBA 01/2024
1	Fc Receptors (Fc Receptor)IBA 01/2024
1	vinyltriethoxysilane (VTES)IBA 11/2022
1	InterferonsIBA 01/2022
1	Etoposide (VP 16)FDA LinkGeneric 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	7- chloro- 8- hydroxy- 1- (3'- iodophenyl)- 3- methyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepine (TISCH)IBA 12/2021
1	Histone Deacetylase InhibitorsIBA 11/2021
1	SteroidsIBA 10/2021
1	Immunologic Factors (Immunomodulators)IBA 09/2021
1	isatuximabIBA 01/2021
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	insulin receptor-related receptor (IRR)IBA 01/2021
1	bismuth subsalicylate (Pepto-bismol)FDA LinkGeneric 01/2020
1	Serotonin 5-HT3 Receptor AntagonistsIBA 01/2020
1	Loperamide (Imodium)FDA LinkGeneric 01/2020
1	MegestrolIBA 01/2020
1	Methylphenidate (Ritalin)FDA LinkGeneric 01/2020
1	Neurokinin-1 Receptor AntagonistsIBA 01/2020
1	Protein Subunit VaccinesIBA 01/2020
1	CannabinoidsIBA 01/2020
1	VaccinesIBA 01/2020

Therapy/Procedure

55	Therapeutics 04/2024 - 01/2013
7	Stem Cell Transplantation 04/2024 - 09/2015
4	Immunotherapy 01/2024 - 01/2016
4	Transplantation 10/2023 - 07/2010
2	Salvage Therapy 03/2024 - 01/2023
2	Duration of Therapy 11/2023 - 01/2018
2	Aftercare (After-Treatment) 01/2023 - 10/2013
2	Hematopoietic Stem Cell Mobilization 01/2023 - 07/2010
2	Drug Therapy (Chemotherapy) 01/2022 - 06/2015
2	Artificial Respiration (Mechanical Ventilation) 11/2020 - 06/2020
2	Platelet Transfusion (Blood Platelet Transfusions) 01/2020 - 01/2018
1	Retreatment 03/2024
1	Subcutaneous Injections 11/2022
1	Radiotherapy 01/2022
1	Intravenous Infusions 01/2020